These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. Peralta C; Wolf E; Alber H; Seppi K; Müller S; Bösch S; Wenning GK; Pachinger O; Poewe W Mov Disord; 2006 Aug; 21(8):1109-13. PubMed ID: 16622856 [TBL] [Abstract][Full Text] [Related]
27. Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease. Apostolakis EE; Baikoussis NG; Tselikos D; Koniari I; Prokakis C; Fokaeas E; Karanikolas M J Cardiothorac Surg; 2009 Nov; 4():65. PubMed ID: 19912629 [TBL] [Abstract][Full Text] [Related]
28. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide. Růzicka E; Línková H; Penicka M; Ulmanová O; Nováková L; Roth J J Neurol; 2007 Nov; 254(11):1575-8. PubMed ID: 17712588 [TBL] [Abstract][Full Text] [Related]
30. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008. Ooba N; Yamaguchi T; Kubota K Drug Saf; 2011 Apr; 34(4):329-38. PubMed ID: 21417505 [TBL] [Abstract][Full Text] [Related]
31. Pergolide associated cardiac valvulopathy based on Ontario administrative data. Zadikoff C; Duong-Hua M; Sykora K; Marras C; Lang A; Rochon P Can J Neurol Sci; 2008 May; 35(2):173-8. PubMed ID: 18574930 [TBL] [Abstract][Full Text] [Related]
33. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Senol MG; Togrol RE Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893 [No Abstract] [Full Text] [Related]
34. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease. Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211 [TBL] [Abstract][Full Text] [Related]
35. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias. Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640 [TBL] [Abstract][Full Text] [Related]
36. Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both. Ozer F; Tiras R; Cetin S; Ozturk O; Aydemir T; Ozben S; Meral H; Kizkin S; Bader H; Ozben B J Clin Neurosci; 2009 Jan; 16(1):83-7. PubMed ID: 19014887 [TBL] [Abstract][Full Text] [Related]
37. Pergolide and valvular heart disease: the lower the better? Droogmans S; Cosyns B; Van Camp G Eur J Echocardiogr; 2008 Nov; 9(6):717-8. PubMed ID: 18641388 [No Abstract] [Full Text] [Related]
38. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis. Lund BC; Neiman RF; Perry PJ Pharmacotherapy; 1999 Dec; 19(12):1437-8. PubMed ID: 10600093 [TBL] [Abstract][Full Text] [Related]
39. Cardiac valvulopathy associated with pergolide use. Zadikoff C; Rochon P; Lang A Can J Neurol Sci; 2006 Feb; 33(1):27-33. PubMed ID: 16583718 [TBL] [Abstract][Full Text] [Related]
40. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. Pohanka M; Kanovský P; Bares M; Pulkrábek J; Rektor I Parkinsonism Relat Disord; 2005 Dec; 11(8):509-12. PubMed ID: 15994112 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]